Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors

X
Trial Profile

Prospective randomIzed Clinical Trial Assessing the Tolerance and Clinical Benefit of feCAl tranSplantation in patientS With melanOma Treated With CTLA-4 and PD1 Inhibitors

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Maa-T-013 (Primary) ; Ipilimumab; Nivolumab; PEG-3350/sodium chloride/sodium sulfate/potassium chloride/ascorbic acid
  • Indications Malignant melanoma
  • Focus Adverse reactions; Proof of concept
  • Acronyms PICASSO
  • Most Recent Events

    • 07 May 2024 According to a MaaT Pharma media release, this phase 2a clinical trial sponsored by AP-HP and in collaboration with INRAE and Institut Gustave Roussy, evaluating MaaT013 in combination with Immune Checkpoint Inhibitors (ICI).
    • 05 Mar 2024 According to a MaaT Pharma media release, topline results are scheduled for communication in the last quarter of 2024 or the first quarter of 2025.
    • 05 Mar 2024 Status changed from recruiting to active, no longer recruiting, according to a MaaT Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top